Silo Pharma Announces Share Buyback Program
Rhea-AI Summary
Silo Pharma (Nasdaq: SILO) announced a board-authorized share repurchase program on February 23, 2026 to acquire up to $1,000,000 of its common stock. The program permits purchases on the open market or in privately negotiated transactions, subject to SEC rules and blackout periods.
The company reported 13,318,273 shares outstanding as of November 13, 2025. The program does not obligate the company to buy any specific number of shares and may be suspended or discontinued at the company's discretion.
Positive
- Board authorization for share repurchase of up to $1,000,000
- Flexible execution via open-market or privately negotiated transactions
Negative
- Repurchase not binding; company may buy no shares at all
- Timing, quantity, and prices depend on market conditions and blackout periods
News Market Reaction – SILO
On the day this news was published, SILO declined 1.82%, reflecting a mild negative market reaction. Argus tracked a peak move of +70.8% during that session. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $69K from the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 7.1x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SILO was down 2.88% pre‑announcement. Peers showed mixed action: ARTL (-6.38%), CERO (-5.44%), PLRZ (-7%), PMCB (-1.58%) declined while ENSC rose 4.74%, pointing to stock‑specific rather than clean sector‑wide pressure.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Patent allowance | Positive | -3.2% | Japan Notice of Allowance expanding SPC-15 patent coverage for PTSD. |
| Dec 30 | Clinical LOI | Positive | +4.7% | LOI with Allucent to support Phase 1 clinical development of SPC-15. |
| Nov 17 | Trial preparation | Positive | -1.1% | Partnership with Allucent to prepare FDA IND submission for SPC-15. |
| Oct 29 | Crypto treasury move | Positive | -1.9% | Selection of Alphaledger T12 Fund as core tokenized RWA investment. |
| Oct 23 | Pipeline & crypto update | Positive | +3.2% | Update on SPC-15 milestones and launch of digital assets treasury program. |
Recent positive company news has more often been met with negative or muted price reactions, with three declines vs. two advances after constructive updates.
Over the past several months, Silo Pharma has focused on advancing SPC-15 for PTSD and expanding its intellectual property. A Feb 18, 2026 Notice of Allowance in Japan and a Dec 30, 2025 LOI with Allucent for Phase 1 clinical development followed earlier collaboration plans and IND-enabling work. The company also pursued a crypto-focused treasury diversification strategy and provided a development and digital assets update on Oct 23, 2025. Against this backdrop, the newly authorized buyback adds a capital allocation element to an R&D- and IP-driven story.
Market Pulse Summary
This announcement adds a capital allocation layer to Silo Pharma’s story, with the board authorizing up to $1 million of common stock repurchases against 13,318,273 shares outstanding as of November 2025. The program is discretionary, subject to market conditions and blackout restrictions, and can be suspended or discontinued. In context of recent IP wins and clinical planning for SPC-15, investors may watch how actively the company utilizes the authorization and how it balances buybacks with development spending.
Key Terms
common stock financial
open market financial
Securities and Exchange Commission regulatory
blackout period regulatory
AI-generated analysis. Not financial advice.
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to
“We believe that the current capital market conditions should allow us to capture additional value for all shareholders through this measured buyback program. Our Board of Directors and executive management team remain committed to delivering value to our shareholders,” said Eric Weisblum, Chief Executive Officer.
The timing, number of shares repurchased, and prices paid for the stock under this program will depend on market conditions and corporate and regulatory limitations, including blackout period restrictions. The repurchase program does not obligate the Company to acquire any specific number of shares, and it may be suspended or discontinued at the Company's discretion.
About Silo Pharma, Inc.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
(800) 705-0120
investors@silopharma.com
FAQ
What did Silo Pharma (SILO) announce on February 23, 2026 about a buyback?
How many Silo Pharma (SILO) shares were outstanding ahead of the buyback announcement?
Will the Silo Pharma (SILO) buyback obligate the company to repurchase a set number of shares?
How will Silo Pharma (SILO) decide timing and prices for repurchases?
Can Silo Pharma (SILO) repurchase shares privately as part of the program?
Does the $1,000,000 repurchase program guarantee shareholder benefit for Silo Pharma (SILO)?
